Literature DB >> 8640239

Biochemical bases of the pharmacological action of the flavonoid silymarin and of its structural isomer silibinin.

A Valenzuela1, A Garrido.   

Abstract

The flavonoid silymarin and one its structural components, silibinin, have been well characterized as hepato-protective substances. However, little is known about the biochemical mechanisms of action of these substances. This review deals with recent investigations to elucidate the molecular action of the flavonoid. Three levels of action have been proposed for silymarin in experimental animals: a) as an antioxidant, by scavenging prooxidant free radicals and by increasing the intracellular concentration of the tripeptide glutathione; b) regulatory action of the cellular membrane permeability and increase of its stability against xenobiotic injury; c) at the nuclear expression, by increasing the synthesis of ribosomal RNA by stimulating DNA polymerase I and by exerting a steroid-like regulatory action on DNA transcription. The specific hepatoprotective action of silibinin against the toxicity of ethanol, phenylhydrazine and acetaminophen is also discussed. It is suggested that the biochemical effects observed for the flavonoid in experimental models may settle the basis for understanding the pharmacological action of silymarin and silibinin.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8640239

Source DB:  PubMed          Journal:  Biol Res        ISSN: 0716-9760            Impact factor:   5.612


  26 in total

1.  Effects of silymarin on hepatitis C virus and haem oxygenase-1 gene expression in human hepatoma cells.

Authors:  Vania Bonifaz; Ying Shan; Richard W Lambrecht; Susan E Donohue; Darcy Moschenross; Herbert L Bonkovsky
Journal:  Liver Int       Date:  2008-08-07       Impact factor: 5.828

2.  Effect of silymarin in the prevention of Cisplatin nephrotoxicity, a clinical trial study.

Authors:  Ali Momeni; Ali Hajigholami; Shohreh Geshnizjani; Soleiman Kheiri
Journal:  J Clin Diagn Res       Date:  2015-04-01

Review 3.  The use of silymarin in the treatment of liver diseases.

Authors:  R Saller; R Meier; R Brignoli
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 4.  Is there any use for nontraditional or alternative therapies in patients with chronic liver disease?

Authors:  N M Bass
Journal:  Curr Gastroenterol Rep       Date:  1999 Feb-Mar

5.  Development of a HPLC-UV assay for silybin-phosphatidylcholine complex (silybinin capsules) and its pharmacokinetic study in healthy male Chinese volunteers.

Authors:  Wei Li; Jun Gao; Hong-Zhi Zhao; Chang-Xiao Liu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2006 Oct-Dec       Impact factor: 2.441

Review 6.  Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions.

Authors:  Tomas Koltai; Larry Fliegel
Journal:  J Evid Based Integr Med       Date:  2022 Jan-Dec

7.  In Vivo Attenuation of Alcohol- and Cadmium Chloride-Induced Testicular Toxicity Modulated by Silymarin in Male Wistar Rat.

Authors:  Blessing Enebeli; Eze Kingsley Nwangwa; Bartholomew Chukwuebuka Nwogueze; Augustina Nzenegu; Ejime Agbonifo-Chijiokwu; Oghenerukevwe Omeru; Emmanuel Ikemefune Ebuwa
Journal:  Biol Trace Elem Res       Date:  2021-11-10       Impact factor: 3.738

8.  Alterations of mast cells and TGF-beta1 on the silymarin treatment for CCl(4)-induced hepatic fibrosis.

Authors:  Da-Hee Jeong; Gi-Ppeum Lee; Won-Il Jeong; Sun-Hee Do; Hai-Jie Yang; Dong-Wei Yuan; Ho-Yong Park; Kyu-Jong Kim; Kyu-Shik Jeong
Journal:  World J Gastroenterol       Date:  2005-02-28       Impact factor: 5.742

9.  Silibinin pretreatment protects against ochratoxin A-mediated apoptosis in primary rat hepatocytes.

Authors:  E Essid; E Petzinger
Journal:  Mycotoxin Res       Date:  2011-04-19       Impact factor: 3.833

10.  Effects of silymarin and pentoxifylline on matrix metalloproteinase-1 and -2 expression and apoptosis in experimental hepatic fibrosis.

Authors:  Eray Kara; Teoman Coşkun; Yavuz Kaya; Okan Yumuş; Seda Vatansever; Ahmet Var
Journal:  Curr Ther Res Clin Exp       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.